Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.
Urszula ŻebrowskaWalentyna BalwierzJarosław WechowskiAleksandra WieczorekPublished in: Targeted oncology (2024)
Survival benefits in patients treated with MAT+ASCT confirm that the procedure should remain an integral part of multimodal therapy. In patients treated with anti-GD2 immunotherapy, limited evidence suggests that omitting MAT+ASCT is associated with an increased risk of relapse, and therefore, a change in clinical practice can currently not be recommended. Evidence suggests the use of tandem MAT+ASCT compared with the single procedure, with greater benefits observed in patients treated with anti-GD2 immunotherapy. Limited evidence also suggests improved survival following MAT+ASCT in relapsed patients, which needs to be viewed in light of emerging chemoimmunotherapy in this setting.
Keyphrases
- stem cell transplantation
- free survival
- high dose
- end stage renal disease
- clinical practice
- chronic kidney disease
- ejection fraction
- newly diagnosed
- minimally invasive
- acute myeloid leukemia
- acute lymphoblastic leukemia
- peritoneal dialysis
- stem cells
- prognostic factors
- cell therapy
- low dose
- pain management
- multiple myeloma
- hodgkin lymphoma
- chronic pain
- patient reported